Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

6-OHDA-treated monkeys have decreased PGP9.5-ir in cardiac nerve bundles and fibers. by Valerie Joers (319079)

“…<p>(<b>A–D</b>) Microphotographs of PGP9.5-positive nerve bundles (<b>A,B</b>) and fibers (<b>C,D</b>) in control and 6-OHDA-treated animals. …”

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Pairwise correlations in APP/PS1 mice are decreased in dCA1, but increased in vCA1. by Udaysankar Chockanathan (18510288)

Spatial information is significantly decreased in dCA1 and vCA1 in APP/PS1 mice. by Udaysankar Chockanathan (18510288)

“…(B) In dCA1, spatial information was decreased in APP/PS1 mice relative to C57BL/6 controls (mean ± std: C57BL/6 = 0.132 ± 0.048, APP/PS1 = 0.128 ± 0.051, p < 0.005, two-sided Wilcoxon rank-sum test, n_C57BL/6 = 305 units from 5 recording sessions, n_APP/PS1 = 180 units from 4 recording sessions). …”

Testicular involution prior to sex change in gilthead seabream is characterized by a decrease in DMRT1 gene expression and by massive leukocyte infiltration-3 by Sergio Liarte (75701)

“…<p><b>Copyright information:</b></p><p>Taken from "Testicular involution prior to sex change in gilthead seabream is characterized by a decrease in DMRT1 gene expression and by massive leukocyte infiltration"</p><p>http://www.rbej.com/content/5/1/20</p><p>Reproductive Biology and Endocrinology 2007;5():20-20.…”

Population entropy in APP/PS1 mice is decreased in dCA1, but increased in vCA1. by Udaysankar Chockanathan (18510288)

<i>Syx5</i> suppression in human cells decreases copper accumulation but does not affect rate of turnover. by Melanie Norgate (234832)

NCM exposure increases hepatic creatine kinase activity and total ATPase activity, which is associated with decreases in hepatic ABCA1, CD36, and L-FABP protein expression and circ... by Ryan J. Mailloux (50825)

Subjects: “…mitochondrial ATP synthase subunit ATP 5A…”

Increasing TPP side chain length decreases melanoma cell viability and clonogenic survival. by Kyle C. Kloepping (9928265)

“…The error bars for all data presented in Fig 2 represent the mean ± SEM. Results demonstrate that TPP derivatives decrease melanoma cell viability and clonogenic survival; and there is a structure-activity relationship between TPP side chain length and decreased viability and clonogenic survival.…”

Decreased motor neuron survival in E18.5 GAD67-deficient (−/−) hypoglossal and phrenic motor nuclei. by Matthew J. Fogarty (283288)